Lannett Corporation LCI Kremmers Acquisition Analysis 2024

Investment thesis on Lannett Corporation highlighting structural benefits from the Kremmers Urban Pharmaceuticals acquisition. Analysis demonstrates 100%+ upside potential through overlooked cash flow improvements, working capital benefits, and conservative valuation relative to generic drug industry peers. Addresses concerns about leverage ratio and bankruptcy risk.